Background
Methods
Patient population and clinical data collection
Single nucleotide polymorphism (SNP) selection and genotyping
Bioinformatics analysis
Statistical analysis
Results
Characteristic | |
---|---|
Localized prostate cancer cohort | |
Patients, n | 458 |
Age at diagnosis | |
Median, years (IQR) | 66 (61–70) |
PSA at diagnosis | |
Median, ng/mL (IQR) | 11.1 (7.1–17.5) |
Pathologic Gleason score, n (%) | |
< 7 | 160 (35.3) |
7 | 232 (51.2) |
> 7 | 61 (13.5) |
Pathologic stage, n (%) | |
T1/T2 | 303 (67.2) |
T3/T4/N1 | 148 (32.8) |
M1 | 0 (0.0) |
Disease progression | |
No | 274 (59.8) |
Yes | 184 (40.2) |
Advanced prostate cancer cohort | |
Patients, n | 324 |
Age at diagnosis | |
Median, years (IQR) | 72 (66–78) |
PSA at ADT initiation | |
Median, ng/mL (IQR) | 32.6 (9.4–123.4) |
Biopsy Gleason score at diagnosis, n (%) | |
< 7 | 70 (22.2) |
7 | 131 (41.5) |
> 7 | 115 (36.4) |
Clinical stage at diagnosis, n (%) | |
T1/T2 | 92 (28.6) |
T3/T4/N1 | 103 (32.0) |
M1 | 127 (39.4) |
PSA nadir | |
Median, ng/mL (IQR) | 0.12 (0.01–1.08) |
Treatment modality | |
ADT as primary treatment | 138 (42.7) |
ADT for post RP PSA failure | 39 (12.1) |
ADT for post RT PSA failure | 6 (1.9) |
Neoadjuvant/adjuvant ADT with RT | 101 (31.3) |
Others | 39 (12.1) |
Disease progression | |
No | 28 (8.6) |
Yes | 296 (91.4) |
Gene | SNP | Genotype | No. of patients | No. of events | 5-year survival rate (%) |
P
a
|
P
b
| HR (95% CI) |
P
c
|
---|---|---|---|---|---|---|---|---|---|
NPAS2
| rs6542993 | AA | 169 | 63 | 59.0 | 1.00 | |||
AT | 229 | 90 | 58.8 | 1.40 (0.99–1.98) | 0.059 | ||||
TT | 57 | 29 | 41.6 | 2.34 (1.45–3.79) |
0.001
| ||||
AT/TT vs AA | 0.164 | 0.153 | 1.53 (1.10–2.14) |
0.012
| |||||
TT vs AA/AT |
0.034
|
0.028
| 1.92 (1.25–2.94) |
0.003
| |||||
Trend |
0.039
|
0.042
| 1.50 (1.18–1.91) |
0.001
|
Gene | SNP | Genotype | No. of patients | No. of events | 5-year survival rate (%) |
P
a
| HR (95% CI) |
P
b
|
---|---|---|---|---|---|---|---|---|
NPAS2
| rs6542993 | AA | 126 | 109 | 17.9 | 1.00 | ||
AT | 150 | 143 | 10.4 | 1.44 (1.09–1.90) |
0.010
| |||
TT | 47 | 43 | 10.9 | 1.05 (0.73–1.53) | 0.782 | |||
AT/TT vs AA |
0.024
| 1.32 (1.01–1.71) |
0.039
| |||||
TT vs AA/AT | 0.362 | 0.87 (0.62–1.22) | 0.419 | |||||
Trend | 0.284 | 1.09 (0.92–1.28) | 0.339 |